Cargando…

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin

PURPOSE: Picoplatin is a new generation platinum designed to overcome platinum resistance. The goal of this study was to assess picoplatin anti-tumor activity and measure various cellular parameters in small-cell lung cancer (SCLC) cells resistant to cell killing by cisplatin and carboplatin. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Chi-Hui, Parham, Christi, Shocron, Ellyn, McMahon, Gerald, Patel, Neela
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102205/
https://www.ncbi.nlm.nih.gov/pubmed/20809122
http://dx.doi.org/10.1007/s00280-010-1435-5
_version_ 1782204359179763712
author Tang, Chi-Hui
Parham, Christi
Shocron, Ellyn
McMahon, Gerald
Patel, Neela
author_facet Tang, Chi-Hui
Parham, Christi
Shocron, Ellyn
McMahon, Gerald
Patel, Neela
author_sort Tang, Chi-Hui
collection PubMed
description PURPOSE: Picoplatin is a new generation platinum designed to overcome platinum resistance. The goal of this study was to assess picoplatin anti-tumor activity and measure various cellular parameters in small-cell lung cancer (SCLC) cells resistant to cell killing by cisplatin and carboplatin. METHODS: We developed several platinum-resistant SCLC cell lines to evaluate picoplatin activity and drug resistance mechanisms in vitro. Drug cytotoxicity was measured by MTS assay. Total cellular platinum accumulation was measured by inductively coupled plasma mass spectrometry (ICP-MS). Whole genome gene expression profiling was carried out by microarray analysis. RESULTS: Picoplatin retained significant cytotoxic activity in platinum-resistant SCLC lines compared to cisplatin and carboplatin. Cellular picoplatin accumulation in platinum-resistant and parental cells was high relative to levels of cellular platinum found in the same cell lines after cisplatin or carboplatin treatment. Gene expression analyses revealed substantial differences in gene expression and highlighted specific annotation clusters in carboplatin-resistant cells. In addition, a similar gene expression pattern was observed in picoplatin-treated carboplatin-resistant and parental cells. CONCLUSIONS: Our study demonstrates that picoplatin can overcome carboplatin and cisplatin resistance. The results suggest decreased platinum accumulation as a potential mechanism of platinum resistance in SCLC cells, provide candidate markers (e.g. several genes in the Hox, glutathione biosynthetic process, and MAGE families) that may serve as signatures for platinum resistance, support distinct effects of picoplatin on SCLC cells compared to other platinums, and provide a rationale to develop picoplatin for the treatment of recurrent SCLC following initial therapy with cisplatin or carboplatin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00280-010-1435-5) contains supplementary material, which is available to authorized users.
format Text
id pubmed-3102205
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31022052011-07-14 Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin Tang, Chi-Hui Parham, Christi Shocron, Ellyn McMahon, Gerald Patel, Neela Cancer Chemother Pharmacol Original Article PURPOSE: Picoplatin is a new generation platinum designed to overcome platinum resistance. The goal of this study was to assess picoplatin anti-tumor activity and measure various cellular parameters in small-cell lung cancer (SCLC) cells resistant to cell killing by cisplatin and carboplatin. METHODS: We developed several platinum-resistant SCLC cell lines to evaluate picoplatin activity and drug resistance mechanisms in vitro. Drug cytotoxicity was measured by MTS assay. Total cellular platinum accumulation was measured by inductively coupled plasma mass spectrometry (ICP-MS). Whole genome gene expression profiling was carried out by microarray analysis. RESULTS: Picoplatin retained significant cytotoxic activity in platinum-resistant SCLC lines compared to cisplatin and carboplatin. Cellular picoplatin accumulation in platinum-resistant and parental cells was high relative to levels of cellular platinum found in the same cell lines after cisplatin or carboplatin treatment. Gene expression analyses revealed substantial differences in gene expression and highlighted specific annotation clusters in carboplatin-resistant cells. In addition, a similar gene expression pattern was observed in picoplatin-treated carboplatin-resistant and parental cells. CONCLUSIONS: Our study demonstrates that picoplatin can overcome carboplatin and cisplatin resistance. The results suggest decreased platinum accumulation as a potential mechanism of platinum resistance in SCLC cells, provide candidate markers (e.g. several genes in the Hox, glutathione biosynthetic process, and MAGE families) that may serve as signatures for platinum resistance, support distinct effects of picoplatin on SCLC cells compared to other platinums, and provide a rationale to develop picoplatin for the treatment of recurrent SCLC following initial therapy with cisplatin or carboplatin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00280-010-1435-5) contains supplementary material, which is available to authorized users. Springer-Verlag 2010-08-31 2011 /pmc/articles/PMC3102205/ /pubmed/20809122 http://dx.doi.org/10.1007/s00280-010-1435-5 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Tang, Chi-Hui
Parham, Christi
Shocron, Ellyn
McMahon, Gerald
Patel, Neela
Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
title Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
title_full Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
title_fullStr Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
title_full_unstemmed Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
title_short Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
title_sort picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102205/
https://www.ncbi.nlm.nih.gov/pubmed/20809122
http://dx.doi.org/10.1007/s00280-010-1435-5
work_keys_str_mv AT tangchihui picoplatinovercomesresistancetocelltoxicityinsmallcelllungcancercellspreviouslytreatedwithcisplatinandcarboplatin
AT parhamchristi picoplatinovercomesresistancetocelltoxicityinsmallcelllungcancercellspreviouslytreatedwithcisplatinandcarboplatin
AT shocronellyn picoplatinovercomesresistancetocelltoxicityinsmallcelllungcancercellspreviouslytreatedwithcisplatinandcarboplatin
AT mcmahongerald picoplatinovercomesresistancetocelltoxicityinsmallcelllungcancercellspreviouslytreatedwithcisplatinandcarboplatin
AT patelneela picoplatinovercomesresistancetocelltoxicityinsmallcelllungcancercellspreviouslytreatedwithcisplatinandcarboplatin